TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01117181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: The target dose is 20 mg per day provided as two 10 mg doses administered orally. Patients will start by taking 10 mg daily (two 5 mg over-encapsulated tablets) for three days, at which time the dose will be increased to 20 mg per day (four 5 mg over-encapsulated tablets). In the event of significant side-effects, the dose will be reduced to a minimum of 10 mg per day. The study drug will be administered for 6 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Patients will start with two capsules of placebo for three days, at which time the dose will be increased to four capsules. The dose may be reduced to a minimum of two capsules per day if there appears to be significant side-effects. Placebo will be administered for 6 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychosocial intervention
Description: The psychosocial intervention will consist of three components: a counseling session, the provision of education materials, and 24-hour availability for crises.~The counseling session, in which a trained study clinician will counsel the primary caregiver, lasts approximately 20-30 minutes, and consists of the following elements:~* Review and adjustment of the patient and caregiver supportive care plans~* Emotional support and opportunity to ventilate feelings~* Counseling regarding specific caregiving skills~* Assistance with problem solving of specific issues that the caregiver brings to the sessions~* Answers for questions regarding the educational materials~The educational materials will consist of a copy of the book The 36-Hour Day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Psychosocial intervention
Description: The psychosocial intervention will consist of three components: a counseling session, the provision of education materials, and 24-hour availability for crises.~The counseling session, in which a trained study clinician will counsel the primary caregiver, lasts approximately 20-30 minutes, and consists of the following elements:~* Review and adjustment of the patient and caregiver supportive care plans~* Emotional support and opportunity to ventilate feelings~* Counseling regarding specific caregiving skills~* Assistance with problem solving of specific issues that the caregiver brings to the sessions~* Answers for questions regarding the educational materials~The educational materials will consist of a copy of the book The 36-Hour Day
Study: NCT03016039

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcumin supplementation
Description: use of curcumin supplementation as an additive treatment to the conventional treatment
Study: NCT03140488

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Patients will be randomized to low dose or high dose oxytocin for induction of labor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Patients will be randomized to low dose or high dose oxytocin for induction of labor.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Patients will be randomized to low dose or high dose oxytocin for induction of labor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Patients will be randomized to low dose or high dose oxytocin for induction of labor.
Study: NCT03718468

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC FLU Quadrivalent
Description: A single dose administration of GC FLU Quadrivalent will be through intramuscular injection.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluarix Tetra
Description: A single dose administration of Fluarix Tetra will be through intramuscular injection.
Study: NCT03001414

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo followed by Autologous EPCs transfected with human eNOS
Description: 4 doses of placebo in first 6 months followed by 4 doses of autologous EPCs transfected with eNOS in second 6 months

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous EPCs transfected with human eNOS followed by Placebo
Description: 4 doses of autologous EPCs transfected with eNOS in first 6 months followed by 4 doses of placebo in second 6 months

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous EPCs transfected with human eNOS
Description: 4 doses of autologous EPCs transfected with eNOS in first 6 months which is repeated in second 6 months
Study: NCT00004889

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 375 mg/m2 given as an intravenous (IV) infusion once weekly for four doses (days 1, 8, 15, and 22). For purposes of this study 4 weekly courses will constitute one cycle of therapy.
Study: NCT02165644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Description: Acetazolamide 250 mg QID oral for 4 days along with standard of care which includes Nimodipine 60 mg orally every 4 hours, with therapy starting within 96 hours of the event and continued for 21 days.~If the drug can't be given orally, then feeding tube (NG Tube or DHT) will be used for drug administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimodipine
Description: Nimodipine 60 mg orally every 4 hours, with therapy starting within 96 hours of the event and continued for 21 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nimodipine
Description: Nimodipine 60 mg orally every 4 hours, with therapy starting within 96 hours of the event and continued for 21 days
Study: NCT00807443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: Raltegravir (INN), 400 mg tablets, developed and supplied by Merck Sharp \& Dohme. A dose of 400 mg will be administered every 12 hours
Study: NCT03288623

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dark Chocolate (85% cocoa)
Description: Dark chocolate (85% cocoa) in tablet

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: White/Milk chocolate (<35% cocoa)
Description: white or milk chocolate (\<35% cocoa) in tablet
Study: NCT02912962

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Regulation Intervention adapted from the Alert Program ®
Study: NCT01678911

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gralise
Description: Subjects will start at 600mg and titrate up by 600mg a week for two weeks (to 1800mg), then remain on 1800mg steady state dose of medication (or placebo pills) for 2 weeks. If intolerable side effects occur, the dose may be reduced to last tolerable dose at the discretion of the PI. A 2-week down-titration will be used. Subjects will have 1 week of wash-out before repeating the above procedure for the other arm of the study (placebo or medication).
Study: NCT04649060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melflufen
Description: Powder for solution for i.v. infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Solution for s.c. injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daratumumab
Description: Solution for s.c. injection
Study: NCT01823198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study: NCT01427686

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dobutamine
Description: Start Dobutamine with 5µg/kg/min. Increase as needed until mean arterial pressure is in normal range (defined by responsible neonatologist, usually between gestational age in weeks and 10mmHg above this threshold) or until a maximum dose of 15µg/kg/min is reached. Only in the latter case switch to Dopamine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dopamine
Description: Start Dopamine with 5µg/kg/min. Increase as needed until mean arterial pressure is in normal range (defined by responsible neonatologist, usually between gestational age in weeks and 10mmHg above this threshold) or until a maximum dose of 15µg/kg/min is reached. Only in the latter case switch to Dobutamine.
Study: NCT02036294

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BREATHE program
Description: A patient and family- centered transitional care intervention that includes a comprehensive biopsychosocial assessment, a tailored treatment plan, a tailored disease management program, and care management support services .

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Standard Healthcare Services
Study: NCT03498027

Intervention type: DEVICE
Intervention: TaqMan Bacillus anthracis Detection Kit
Description: The TaqMan® Bacillus anthracis Detection Kit is composed of the Applied Biosystems® 7500 Fast Dx Real-Time PCR Instrument with SDS Software, secondary interpretative software, and lyophilized reagents for the detection of gene targets for B. anthracis. The test assay is a multiplexed assay targeting gene targets for B. anthracis, in addition to an internal positive control. Reagents are lyophilized as a fully formulated Mastermix and are stable at room temperature for up to two years. The kit is specifically designed for performing real-time PCR using the Applied Biosystems® 7500 Fast Dx Real-Time PCR Instrument with SDS Software , with nucleic acids extracted from clinical specimens using Qiagen's QIAamp® Blood Midi Kit manual extraction or Roche MagNAPure automated extraction methods.
Study: NCT04022993

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lantus Solostar, 100 Units/mL Subcutaneous Solution
Description: 4 weeks of glucose-level based dose titration, 22 weeks of treatment with stable doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin RinGlar, 100 Units/mL Subcutaneous Solution
Description: 4 weeks of glucose-level based dose titration, 22 weeks of treatment with stable doses
Study: NCT00961233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inhaled/swallowed budesonide
Description: medication will be nebulized and then swallowed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: viscous/swallowed budesonide
Description: viscous suspension of budesonide will be swallowed
Study: NCT04343547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP16001
Description: Tablets, Oral, once daily single dose
Study: NCT01823198

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo allogeneic PBSC transplant
Study: NCT04343547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWC202001+DWC202002
Description: Tablets, Oral, multiple doses of DWC202001 and DWC202002 in combination
Study: NCT03933800

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High flow nasal cannula
Description: High flow nasal cannula therapy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous positive airway pressure
Description: Continuous positive airway pressure therapy
Study: NCT04343547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP16001+DWC202001+DWC202002
Description: Tablets, Oral, DWP16001 , DWC202001 and DWC202002 in combination
Study: NCT03338881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-TAK-659
Description: \[14C\]-TAK-659 solution.
Study: NCT00904644

Intervention type: DRUG
Intervention: Raltegravir
Description: Raltegravir standard dosage of 400mg tablets every 12 hours together with an optimized backbone antiretroviral drug regimen
Study: NCT03338881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-659
Description: TAK-659 tablets.
Study: NCT03537105

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin biopsies
Description: Two skin biopsies (4mm punch) are performed under local anesthesia at the site of cutaneous inflammation/fibrosis.
Study: NCT00257543

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Alternative donor bone marrow and cord blood
Description: bone marrow transplant - alternative donors for bone marrow and cord blood transplants
Study: NCT00921570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: calcium channel blocker (Amlodipine 10 mg) during 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: calcium channel blocker (Amlodipine 10 mg) during 12 weeks
Study: NCT01823198

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT00003587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: AUC=5.5 day 1 every 21 days X 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: IV cisplatin 100 mg/m\^2 day 1 every 21 days X 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: IV docetaxel 75 mg/m\^2 day 1 every 21 days X 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: IV gemcitabine 1,000 mg/m\^2/day, days 1 and 8 every 21 days X3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: IV paclitaxel 225 mg/m\^2/day, day 1 every 21 days X 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine
Description: IV vinorelbine 25 mg/m\^2/day, days 1 and 8 every 21 days X 3
Study: NCT03899233

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fractional CO2 laser
Description: Low power fractional CO2 laser with a power of 12 watts, spacing 800 micrometer (7.3% density), and dwell time 300 microsecond

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid intradermal microinjections
Description: Tranexamic acid 500mg/5ml ampules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid intradermal microinjections
Description: Tranexamic acid 500mg/5ml ampules
Study: NCT02458287

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bococizumab 75mg
Description: Bococizumab autoinjector (pre-filled pen) combination Product. 75mg every 2 weeks for 10 weeks, subcutaneous injection.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Bococizumab 150mg placebo
Description: Bococizumab placebo autoinjector (pre-filled pen) combination Product. 150mg placebo every 2 weeks for 10 weeks, subcutaneous injection.
Study: NCT00921570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: AII receptor blocker inhibitor (Valsartan 160 mg) during 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: AII receptor blocker inhibitor (Valsartan 160 mg) during 12 weeks
Study: NCT01285414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verubulin
Description: Verubulin, dose determined in Part A, i.v. once weekly, Temozolomide \& Radiation Therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide & Radiation Therapy
Description: Temozolomide \& Radiation Therapy
Study: NCT03248817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: single shot phenylephrine
Description: a single shot of phenylephrine (1.5 mcg/Kg) will be administrated intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fixed infusion phenylephrine
Description: fixed infusion of phenylephrine will be administrated at a rate of 0.75 mcg/Kg/min.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: variable infusion phenylephrine
Description: Variable infusion of phenylephrine will be administrated at a starting rate of 0.75 mcg/Kg/min.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Bupivacaine will be administrated in the subarachnoid space for spinal anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Bupivacaine will be administrated in the subarachnoid space for spinal anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Bupivacaine will be administrated in the subarachnoid space for spinal anesthesia
Study: NCT03415672

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HBVaxPro
Description: Three doses of HBVaxPro-10μg at 0, 1, and 2 months. The HBVaxPro-10μg vaccines are administered strictly intramuscularly in the deltoid muscle and must not be injected intravascularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBAI20
Description: Three doses of HBAI20 at 0, 1, and 2 months. The HBAI20 vaccines are administered strictly intramuscularly in the deltoid muscle and must not be injected intravascularly.
Study: NCT01183481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Description: Patients will be given a single dose of Aprepitant 125 mg on Day 0 (at least one hour before on the day of RT) followed by 80 mg of Aprepitant once daily in the mornings on Days 1 and 2 following the radiation treatment.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Palliative radiation therapy
Description: Moderately emetogenic palliative radiation therapy (RT) will be administered to all patients on the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granisetron
Description: Patients will be given a single dose of both Granisetron 2 mg orally on Day 0 (at least one hour before on the day of RT).
Study: NCT01041001

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cartistem
Description: allogeneic-unrelated umbilical cord blood-derived mesenchymal stem cell product

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microfracture treatment
Study: NCT02458287

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Bococizumab 75mg placebo
Description: Bococizumab placebo autoinjector (pre-filled pen) combination product. 75mg placebo every 2 weeks for 10 weeks, subcutaneous injection.
Study: NCT00384644

Intervention type: DEVICE
Intervention: NiRS measurment of tissue oxygenation
Description: NiRS measurment of tissue oxygenation

Intervention type: DEVICE
Intervention: NiRS measurment of tissue oxygenation
Description: NiRS measurment of tissue oxygenation
Study: NCT04264494

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRP intra articular injection
Description: Fifty RA patients were injected intra-articularly with 3 doses of PRP at 4 weeks intervals for the joints with only tenderness (arthralgia without swelling or effusion) and revaluated at 3 and 6 months post the last injection regarding the same evaluating tools.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: NACL intra articular injection
Description: and 50 patients who serve as a control and injected intra-articularly with 3 doses of placebo (NaCl saline) at 4 weeks intervals for the joints with only tenderness (arthralgia without swelling or effusion) and revaluated at 3 and 6months post last injection regarding the same evaluating tools.
Study: NCT02763267

Intervention type: OTHER
Intervention: Oral glucose tolerance test
Description: 75 gram oral glucose tolerance test (fasting) at: Visit 1 (pregnant \[4-14 weeks gestation\] and nonpregnant women); Visit 2 (pregnant subjects only at 24-28 weeks gestation); Visit 3 (pregnant subjects only at 6-12 weeks postpartum)

Intervention type: OTHER
Intervention: Oral glucose tolerance test
Description: 75 gram oral glucose tolerance test (fasting) at: Visit 1 (pregnant \[4-14 weeks gestation\] and nonpregnant women); Visit 2 (pregnant subjects only at 24-28 weeks gestation); Visit 3 (pregnant subjects only at 6-12 weeks postpartum)
Study: NCT01095939

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets; oral administration; once a day for 6 months. After this period of 6 months blinded treatment, the treatment will be stopped for 2 weeks. At the end of this washout period, a new renal evaluation is done. At that time, opened label treatment will be proposed to the women who still show renal alterations after a 2 weeks washout period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benazepril hydrochloride
Description: Tablets (10 or 20 mg); oral administration; once a day for 6 months. After this period of 6 months blinded treatment, the treatment will be stopped for 2 weeks. At the end of this washout period, a new renal evaluation is done. At that time, opened label treatment will be proposed to the women who still show renal alterations after a 2 weeks washout period
Study: NCT00442130

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GM-K562 vaccine
Description: The vaccine will be administered over 1 cycle of 7 weeks, that begins 1 month after stem cell transplant. The vaccine will be given 6 times over 2 months -- once a week for three weeks then every other week for 3 vaccines.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stem cell transplantation
Description: Participants will be admitted to the hospital for approximately 8 days to receive chemotherapy and stem cell transplantation
Study: NCT02364661

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Over night starvation (fasting)
Description: HBV viral load will be analyzed after over-night starvation versus following a morning meal
Study: NCT01736930

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pump suspension
Description: The study laptop will communicate to the pump causing suspension based on output from the algorithm which predicts hypoglycemia based on the continuous glucose sensor trend.
Study: NCT01100762

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cranial Electric Stimulation (CES)
Description: We will follow the procedure described by several investigators as safe and effective. The participant will sit on a standard chair. Two commercially available surface electrodes will be embedded in an elastic head cup. Each electrode will be covered with a water soaked absorbent fabric. One positive (+) electrode will be placed over the primary motor cortex (M1) and pre-motor areas. One negative (-) electrode will be placed over the skin overlying the contra lateral supra-orbital region. The electrodes will be connected via 2 leads to a battery powered direct current stimulator. The stimulator will be programmed to deliver 0.975mA (peak 4mA) over 20 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treadmill
Description: The participant will walk on a treadmill for 20 minutes at the individually self-selected velocity determined at baseline.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CES and Treadmill
Description: Participants will have a combined session with CES while walking on the treadmill for 20 minutes at the individually self-selected velocity determined at baseline.